---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-011612"
form_type: "8-K"
ticker: "REVB"
cik: "0001810560"
company_name: "REVELATION BIOSCIENCES, INC."
filed_at: "2023-04-03T23:59:59+00:00"
generated_at: "2026-06-17T07:12:11.152966+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Revelation Biosciences reports FY2022 net loss $10.8M; cash $5.3M through June 2024

## Summary
- Cash and cash equivalents $5.3M at Dec 31, 2022 vs $1.3M year ago; $15.6M public offering completed.
- Net loss for FY2022 $10.8M ($20.09 per share) vs $12.0M ($42.50 per share) in 2021.
- Operating cash burn $11.2M for FY2022 vs $11.1M in prior year.
- Plans to start combined Phase 1a clinical study for REVTx-300 and REVTx-100 in H2 2023.
- Management believes cash sufficient to fund operations through June 2024.

## SEC filing metadata
- accession: 0000950170-23-011612
- form_type: 8-K
- ticker: REVB
- cik: 0001810560
- company_name: REVELATION BIOSCIENCES, INC.
- filed_at: 2023-04-03T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/0000950170-23-011612-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/revb-20230330.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-011612
- JSON: https://secwatch.observer/filing/0000950170-23-011612.json
- Plain text: https://secwatch.observer/filing/0000950170-23-011612.txt

## Key facts
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported twelve months ended December 31, 2022 results: net income $10.8 million, EPS $20.09 per share.
  - Period: twelve months ended December 31, 2022
  - Net income: $10.8 million
  - EPS: $20.09 per share
  - Result: reported results
  source text: Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/0000950170-23-011612-index.htm
- Earnings Releases
  REVELATION BIOSCIENCES, INC. reported three months ended December 31, 2022 results: net income $1.2 million, EPS $1.77 per share.
  - Period: three months ended December 31, 2022
  - Net income: $1.2 million
  - EPS: $1.77 per share
  - Result: reported results
  source text: Revelation’s net loss for the three and twelve months ended December 31, 2022 was $1.2 million and $10.8 million, or $1.77 per share and $20.09 per share, respectively
  evidence_url: https://www.sec.gov/Archives/edgar/data/1810560/000095017023011612/0000950170-23-011612-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.